An mRNA-delivered consensus allergen induces a neutralizing IgG response against food and pollen allergens

Cross-allergies affect a significant proportion of the population, and contribute to detrimental health and socioeconomic impacts, yet allergen immunotherapies often target a single allergen source disregarding cross-reactive allergens from other sources. Here we introduce an immunization approach developed for improved desensitization in cross-allergic patients using a consensus allergen (cnsLTP1), which contains orthologous non-specific lipid transfer proteins (nsLTP) derived from relevant fruit and pollen allergens. In BALB/c mice, vaccination via either mRNA-lipid nanoparticle (LNP) vehicle or traditional protein formulation induces cnsLTP1-specific IgGs capable of recognizing and binding to multiple nsLTPs. These IgGs block allergen binding by patient serum IgEs and prevent humanized rat basophil degranulation in vitro. Meanwhile, in an allergic mouse model, the mRNA-LNP formulation is tolerated and induces allergen-specific IgG responses but does not ameliorate subsequent allergen challenge responses. Regardless, this cross-allergen mRNA-LNP-based immunotherapy may have translation value once route of administration, formulation and/or dosing are optimized.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-02-05
DOI
https://doi.org/10.1038/s41467-026-69134-4
Primary Topic
Food Allergy and Anaphylaxis Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An mRNA-delivered consensus allergen induces a neutralizing IgG response against food and pollen allergens

Carlos J. Aranda, Lasse Frank Voss, Andreas H. Laustsen, Timothy P. Jenkins et al.
Nature Communications
Food Allergy and Anaphylaxis Research
article

An mRNA-delivered consensus allergen induces a neutralizing IgG response against food and pollen allergens

Carlos J. Aranda, Lasse Frank Voss, Andreas H. Laustsen, Timothy P. Jenkins, Rasmus Münter, K. Johansen, Jens Vindahl Kringelum, Josefine K. Corneliussen, Helena Højsted Eriksen, J Bartra, Mariona Pascal, M. Paz Villalba, Esperanza Rivera-de-Torre, Olga Luengo, Mark Møiniche, Jorge Parrón-Ballesteros, Sine Reker Hadrup, Blanca Morillo, Javier Turnay, Cristobalina Mayorga, Juan L. Paris, Ulrikke F. Furland
article en

Abstract

Cross-allergies affect a significant proportion of the population, and contribute to detrimental health and socioeconomic impacts, yet allergen immunotherapies often target a single allergen source disregarding cross-reactive allergens from other sources. Here we introduce an immunization approach developed for improved desensitization in cross-allergic patients using a consensus allergen (cnsLTP1), which contains orthologous non-specific lipid transfer proteins (nsLTP) derived from relevant fruit and pollen allergens. In BALB/c mice, vaccination via either mRNA-lipid nanoparticle (LNP) vehicle or traditional protein formulation induces cnsLTP1-specific IgGs capable of recognizing and binding to multiple nsLTPs. These IgGs block allergen binding by patient serum IgEs and prevent humanized rat basophil degranulation in vitro. Meanwhile, in an allergic mouse model, the mRNA-LNP formulation is tolerated and induces allergen-specific IgG responses but does not ameliorate subsequent allergen challenge responses. Regardless, this cross-allergen mRNA-LNP-based immunotherapy may have translation value once route of administration, formulation and/or dosing are optimized.

Nature CommunicationsVol. 17(1)
Universidad Complutense de Madrid (ES), Statistics Denmark (DK), Universidad de Granada (ES), Hospital Regional Universitario de Málaga (ES), Instituto de Investigación Biosanitaria de Granada (ES), Hospital Clínic de Barcelona (ES), Vall d'Hebron Hospital Universitari (ES), Andalusian Centre for Nanomedicine and Biotechnology (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Technical University of Denmark (DK)
Villum Fonden, Innovationsfonden, European Commission, Lundbeckfonden
Zero hunger
Openalex Percentile: Top 71%
Food Allergy and Anaphylaxis Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.